联合治疗应是未来非酒精性脂肪性肝炎临床试验的范例吗？
Should combination therapy be the paradigm for future nonalcoholic steatohepatitis clinical trials?
此外，肝脏基金会估计有5%的美国人患非酒精性脂肪性肝炎。
Additionally, the liver foundation estimates that about 5 percent of Americans have NASH.
我们必须认识到所有非酒精性脂肪性肝炎患者发病机制并不是单一的信号途径。
I think that it probably has to do with the fact that the pathogenesis of all patients with non-alcoholic steatohepatitis, is probably not a single way or a single pathway.
新的研究包括55个患非酒精性脂肪性肝炎且有胰岛素抵抗或2型糖尿病的患者。
The new study included 55 people with nonalcoholic steatohepatitis and either insulin resistance or type 2 diabetes.
方法选择符合条件的72例非酒精性脂肪性肝炎患者，随机分为治疗组和对照组。
Methods 72 patients with nonalcoholic fatty liver diseases were randomly divided into two groups.
目的观察甜菜碱对实验性非酒精性脂肪性肝炎（NASH）大鼠的保护作用，并探讨其可能机制。
ObjectiveTo investigate the protective effects of betaine on experimental NASH in rats and the possible mechanisms of the protective effects.
非酒精性脂肪性肝炎（NASH）是一种慢性肝脏疾病，自上世纪八十年代以来逐渐被认识并引起重视。
Non-alcoholic steatohepatitis(NASH)is a chronic liver disease. It is known and thought highly from 1980s last century.
非酒精性脂肪性肝炎和其他脂肪性肝病的发病机制：四步模型，包括肝硬化进展的脂质释放和肝微梗阻的作用。
The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis.
非酒精性脂肪性肝炎和其他脂肪性肝病的发病机制：四步模型，包括肝硬化进展的脂质释放和肝微梗阻的作用。
The pathogenesis of nonalcoholic steatohepatitis and other fatty liver diseases: a four-step model including the role of lipid release and hepatic venular obstruction in the progression to cirrhosis.
应用推荐